BACKGROUND: Dabigatran is a recently introduced direct thrombin inhibitor licensed for
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …

In the past decade, antithrombotic therapy research has focused on the development of new
oral anticoagulant drugs to replace vitamin K antagonists for stroke prevention in patients …

BACKGROUND: Stroke and systemic thromboembolism remain critical causes of mortality
and morbidity in patients with paroxysmal or persistent atrial fibrillation. Dabigatran etexilate …

The use of novel anticoagulants such as dabigatran are increasing. Despite increased risks
of intracerebral haemorrhage with warfarin among Asians, there is little published data on …

Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of
Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were …

Dabigatran is an oral direct thrombin inhibitor (DTI), which has a rapid onset of action and
can be given twice daily (bid) without anticoagulation monitoring. To determine the long term …

Background: In the RELY trial, the novel oral anticoagulant (NOAC) dabigatran has been
found to be at least as effective and safe as warfarin for stroke prevention in atrial fibrillation …

The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF)
demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …